
Feature|Articles|March 3, 2026
Medicaid Expansion Leads to Long-Term Survival Trends in Breast Cancer
Author(s)Sabrina Serani, Oluwasegun Akinyemi, MD, PhD
Fact checked by: Paige Britt
New study links Medicaid expansion to sustained breast cancer survival gains, revealing uneven benefits by race and urging policy action.
Advertisement
Advertisement
For Oluwasegun Akinyemi, MD, PhD, the journey toward researching US health policy began thousands of miles away. As an obstetrician and gynecologist in Nigeria, Akinyemi witnessed a recurring, heartbreaking pattern: women presenting with advanced-stage diseases when clinical intervention could offer little hope. This experience fueled a career transition from the bedside to the legislative data sheet.
Related to this article

Mark A. Lewis, MD, explains when unexpected disease behavior in neuroendocrine tumors should prompt a specialist referral and how patients can still be treated close to home.

Arvind Dasari, MD, MS, explains how to sequence radioligand therapy, cabozantinib, and everolimus in well-differentiated neuroendocrine tumors.

Ravi Parikh, MD, MPP, discusses the future of oncology practice, including real-world data, patient engagement, emerging technologies, and policy priorities shaping cancer care.

Renuka Iyer, MD, discusses clear documentation for AI ambient scribes and why multidisciplinary tumor boards remain essential in neuroendocrine tumor care.

Aman Chauhan, MD, reviews DAREON-7 data on obrixtamig plus chemotherapy in DLL3-positive neuroendocrine carcinoma, including response rates by DLL3 level.

Jacob Sands, MD, of Dana-Farber Cancer Institute, discusses survival gains, durability, and safety of tarlatamab plus durvalumab in the phase 3 DeLLphi-305 trial.

Among patients surveyed, 92% preferred home-based treatment, while nationwide modeling projected substantial savings in oncology resources.
Advertisement
Advertisement
